The European Commission has opened formal antitrust proceedings against Sanofi over the French pharmaceutical company’s marketing of its influenza vaccine for at‑risk seniors, Efluelda. At issue is whether Sanofi’s promotional approach for the product may have breached EU competition law.
Launching a formal case means Brussels sees at least potential competition risks in how a major vaccine producer positioned one of its products in a significant public health segment. The Commission has not alleged wrongdoing at this stage. Still, the step moves Sanofi under closer regulatory watch, similar to earlier EU investigations into pricing or market‑access conduct within the vaccine industry. Attention will likely fall on whether any promotional or contracting practices limited competitors’ access to senior populations, a recurring concern in seasonal flu tenders run through national health systems.
For the industry, the matter highlights how EU competition enforcement is pushing further into vaccine distribution and marketing behavior, beyond familiar price‑fixing or supply collusion issues. Should Brussels ultimately find a violation, the ruling could influence how large vaccine producers design campaigns for older adults and craft their national‑tender strategies. Whether the inquiry stays centered on Efluelda or widens to other products or suppliers will be closely watched. That distinction could signal either a company‑specific case, or a broader look at the sector itself.
